This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jia, Z. Articles by Xie, K. Search for Related Content PubMed Articles by Jia, Z. Articles by Xie, K.

Molecular Basis of the Synergistic Antiangiogenic Activity of Bevacizumab and Mithramycin A

Departments of ¹ Gastrointestinal Medical Oncology and ² Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; ³ Ruijin Hospital, Shanghai Jiaotong University, and ⁴ Cancer Center, Tongji University Affiliated East Hospital, Shanghai, People's Republic of China

Requests for reprints: Keping Xie, Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-2828; Fax: 713-745-1163; E-mail: kepxie{at}mail.mdanderson.org.

The impact of antiangiogenic therapy on the Sp1/vascular endothelial growth factor (VEGF) pathway and that of alteration of Sp1 signaling on the efficacy of antiangiogenic therapy is unclear, yet understanding their interactions has significant clinical implications. Treatment with bevacizumab, a neutralizing antibody against VEGF, suppressed human pancreatic cancer growth in nude mice. Gene expression analyses revealed that this treatment substantially up-regulated the expression of Sp1 and its downstream target genes, including VEGF and epidermal growth factor receptor, in tumor tissues, whereas it did not have this effect on pancreatic cancer cells in culture. Treatment with mithramycin A, an Sp1 inhibitor, suppressed the expression of Sp1 and its downstream target genes in both cell culture and tumors growing in nude mice. Combined treatment with bevacizumab and mithramycin A produced synergistic tumor suppression, which was consistent with suppression of the expression of Sp1 and its downstream target genes. Thus, treatment with bevacizumab may block VEGF function but activate the pathway of its expression via positive feedback. Given the fact that Sp1 is an important regulator of the expression of multiple angiogenic factors, bevacizumab-initiated up-regulation of Sp1 and subsequent overexpression of its downstream target genes may profoundly affect the potential angiogenic phenotype and effectiveness of antiangiogenic strategies for human pancreatic cancer. Therefore, this study is the first to show the significance and clinical implications of alteration of Sp1 signaling in antiangiogenic therapy for pancreatic cancer and other cancers. [Cancer Res 2007;67(10):4878–85]

This article has been cited by other articles:

				M. Bataller, C. Mendez, J. A. Salas, and J. Portugal Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells Mol. Cancer Ther., September 1, 2008; 7(9): 2988 - 2997. [Abstract] [Full Text] [PDF]